155 related articles for article (PubMed ID: 36069854)
21. Prognosis of 100 Japanese patients with mycosis fungoides and Sézary syndrome.
Suzuki SY; Ito K; Ito M; Kawai K
J Dermatol Sci; 2010 Jan; 57(1):37-43. PubMed ID: 19931424
[TBL] [Abstract][Full Text] [Related]
22. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.
Molloy K; Jonak C; Woei-A-Jin FJSH; Guenova E; Busschots AM; Bervoets A; Hauben E; Knobler R; Porkert S; Fassnacht C; Cowan R; Papadavid E; Beylot-Barry M; Berti E; Alberti Violetti S; Estrach T; Matin R; Akilov O; Vakeva L; Prince M; Bates A; Bayne M; Wachsmuch R; Wehkamp U; Marschalko M; Servitje O; Turner D; Weatherhead S; Wobser M; Sanches JA; McKay P; Klemke D; Peng C; Howles A; Yoo J; Evison F; Scarisbrick J
Br J Dermatol; 2020 Mar; 182(3):770-779. PubMed ID: 31049926
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009.
Talpur R; Singh L; Daulat S; Liu P; Seyfer S; Trynosky T; Wei W; Duvic M
Clin Cancer Res; 2012 Sep; 18(18):5051-60. PubMed ID: 22850569
[TBL] [Abstract][Full Text] [Related]
24. Mycosis fungoides and Sézary syndrome: a population-wide study on prevalence and health care use in Finland in 1998-2016.
Keto J; Hahtola S; Linna M; Väkevä L
BMC Health Serv Res; 2021 Feb; 21(1):166. PubMed ID: 33618714
[TBL] [Abstract][Full Text] [Related]
25. The Microenvironment's Role in Mycosis Fungoides and Sézary Syndrome: From Progression to Therapeutic Implications.
Pileri A; Guglielmo A; Grandi V; Violetti SA; Fanoni D; Fava P; Agostinelli C; Berti E; Quaglino P; Pimpinelli N
Cells; 2021 Oct; 10(10):. PubMed ID: 34685762
[TBL] [Abstract][Full Text] [Related]
26. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
27. Mycosis fungoides and Sézary syndrome.
Jonak C; Tittes J; Brunner PM; Guenova E
J Dtsch Dermatol Ges; 2021 Sep; 19(9):1307-1334. PubMed ID: 34541796
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factor analysis in mycosis fungoides/Sézary syndrome.
Diamandidou E; Colome M; Fayad L; Duvic M; Kurzrock R
J Am Acad Dermatol; 1999 Jun; 40(6 Pt 1):914-24. PubMed ID: 10365922
[TBL] [Abstract][Full Text] [Related]
29. Clinical and Histological Characteristics of Mycosis Fungoides and Sézary Syndrome: A Retrospective, Single-centre Study of 43 Patients from Eastern Denmark.
Nielsen PR; Eriksen JO; Wehkamp U; Lindahl LM; Gniadecki R; Fogh H; Fabricius S; Bzorek M; Ødum N; Gjerdrum LM
Acta Derm Venereol; 2019 Dec; 99(13):1231-1236. PubMed ID: 31620804
[TBL] [Abstract][Full Text] [Related]
30. Racial Disparities in the Clinical Presentation and Prognosis of Patients with Mycosis Fungoides.
Huang AH; Kwatra SG; Khanna R; Semenov YR; Okoye GA; Sweren RJ
J Natl Med Assoc; 2019 Dec; 111(6):633-639. PubMed ID: 31623818
[TBL] [Abstract][Full Text] [Related]
31. Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy.
Kamijo H; Miyagaki T
Curr Treat Options Oncol; 2021 Jan; 22(2):10. PubMed ID: 33415447
[TBL] [Abstract][Full Text] [Related]
32. Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk-stratification, and management.
Hristov AC; Tejasvi T; Wilcox RA
Am J Hematol; 2019 Sep; 94(9):1027-1041. PubMed ID: 31313347
[TBL] [Abstract][Full Text] [Related]
33. Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sézary syndrome than quantification of CD26- or CD7- CD4+ T-cells.
Lyapichev KA; Bah I; Huen A; Duvic M; Routbort MJ; Wang W; Jorgensen JL; Medeiros LJ; Vega F; Craig FE; Wang SA
Cytometry B Clin Cytom; 2021 Mar; 100(2):183-191. PubMed ID: 32667737
[TBL] [Abstract][Full Text] [Related]
34. [Mycosis fungoides and Sézary syndrome : a systematic review].
André F; Guenova E; Blanchard G
Rev Med Suisse; 2022 Mar; 18(775):578-589. PubMed ID: 35353453
[TBL] [Abstract][Full Text] [Related]
35. Racial Disparities in Mycosis Fungoides/Sézary Syndrome-A Single-Center Observational Study of 292 Patients.
Gandham AR; Geller S; Dusza SW; Kupper TS; Myskowski PL
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e174-e180. PubMed ID: 38245472
[TBL] [Abstract][Full Text] [Related]
36. Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome.
Kann BH; Park HS; Yeboa DN; Aneja S; Girardi M; Foss FM; Roberts KB; Wilson LD
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):520-526.e2. PubMed ID: 28655598
[TBL] [Abstract][Full Text] [Related]
37. Comparison between the histopathological and immunophenotypical features of hypopigmented and nonhypopigmented mycosis fungoides: A retrospective study.
Jayasinghe DR; Dissanayake K; de Silva MVC
J Cutan Pathol; 2021 Apr; 48(4):486-494. PubMed ID: 32965737
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases.
Benner MF; Jansen PM; Vermeer MH; Willemze R
Blood; 2012 Feb; 119(7):1643-9. PubMed ID: 22160616
[TBL] [Abstract][Full Text] [Related]
39. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium.
Quaglino P; Maule M; Prince HM; Porcu P; Horwitz S; Duvic M; Talpur R; Vermeer M; Bagot M; Guitart J; Papadavid E; Sanches JA; Hodak E; Sugaya M; Berti E; Ortiz-Romero P; Pimpinelli N; Servitje O; Pileri A; Zinzani PL; Estrach T; Knobler R; Stadler R; Fierro MT; Alberti Violetti S; Amitay-Laish I; Antoniou C; Astrua C; Chaganti S; Child F; Combalia A; Fabbro S; Fava P; Grandi V; Jonak C; Martinez-Escala E; Kheterpal M; Kim EJ; McCormack C; Miyagaki T; Miyashiro D; Morris S; Muniesa C; Nikolaou V; Ognibene G; Onida F; Osella-Abate S; Porkert S; Postigo-Llorente C; Ram-Wolff C; Ribero S; Rogers K; Sanlorenzo M; Stranzenbach R; Spaccarelli N; Stevens A; Zugna D; Rook AH; Geskin LJ; Willemze R; Whittaker S; Hoppe R; Scarisbrick J; Kim Y
Ann Oncol; 2017 Oct; 28(10):2517-2525. PubMed ID: 28961843
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome.
Kim YH; Bishop K; Varghese A; Hoppe RT
Arch Dermatol; 1995 Sep; 131(9):1003-8. PubMed ID: 7661601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
